Accuray, Sunnyvale, Calif, has launched the new CyberKnife S7 System, a robotic, noninvasive radiation therapy device capable of treating cancerous and benign tumors throughout the body as well as neurologic disorders. The platform combines speed, advanced precision, and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments
Many changes can happen during treatment: the patient shifts position, breathes, or coughs, muscles tense and relax, fluids and gasses displace internal organs. This movement can impact the location of the tumor target when the radiation beam is delivered. The CyberKnife System’s motion synchronization technology uses AI to adapt radiation delivery in real-time to patient and/or tumor movement throughout the course of treatment.
The system’s robotic design facilitates the delivery of radiation from potentially thousands of unique angles, significantly expanding the possible positions from which radiation beams can be delivered. The more angles and points in space from which to approach the tumor, the better a physician will be able to maximize radiation dose delivered to the tumor and minimize dose to surrounding healthy tissues. The CyberKnife System is the only device capable of delivering sub-millimetric stereotactic treatments anywhere in the body with speed, efficiency and accuracy—all without the need for human intervention.
Geisinger Wyoming Valley Medical Center is the first in the world to treat patients with the new system.
“Geisinger is dedicated to making exceptional cancer care available to residents of northeastern Pennsylvania, within their community,” says Anand Mahadevan, MD, chairman of radiation oncology at Geisinger Cancer Institute. “We are proud to be the first center in the world to treat patients with the CyberKnife S7 System, an advanced device that will expand the scope of tumors we can treat. Knowing that the system will automatically adapt treatment delivery for patient or tumor movement gives us the confidence to use SRS and SBRT for intra- and extra-cranial disease sites throughout the body, providing meaningful benefits to our patients during and after treatment.”
For more information, visit Accuray Incorporated.